Remicade's pending approval for ulcerative colitis raises questions about new high-tech versus older approaches
November 2005
Remicade's pending approval for ulcerative colitis raises questions about new high-tech versus older approaches.
About 85% of patients with severe disease end up with a colectomy when drugs don't work. But this is changing.
Aminosalicylates. Sulfasalazine, 5-aminosalicylic acid, etc are first-line for mild to moderate disease.
Practical advice for a better career, with unlimited access to CE
Pharmacy Technician's Letter Canada includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 120+ CE courses, including the popular CE-in-the-Letter
- Helpful, in-depth Technician Tutorials
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote